2026-09-20T10:39:16Zhttps://dspace.mit.edu/server/oai/requestoai:dspace.mit.edu:1721.1/902242022-01-13T07:54:52Zcom_1721.1_7582com_1721.1_7581col_1721.1_131023
Robert Pindyck.
Sharma, Shweta Humad
Sloan School of Management.
Sloan School of Management
n-us---
2014-09-19T21:47:05Z
2014-09-19T21:47:05Z
2014
2014
http://hdl.handle.net/1721.1/90224
890374849
Thesis: M.B.A., Massachusetts Institute of Technology, Sloan School of Management, 2014.
Cataloged from PDF version of thesis.
Includes bibliographical references.
There are about 25M (million) diabetics in the US alone, of which only 5-10% of the type 1 diabetics (1M) market has been penetrated with continuous glucose monitoring (CGM) devices. This thesis will provide an overview of the glucose monitoring, then focus on who the key market players for CGM are. Ensuing sections will explore product offerings, understanding what features patients care for and what critical limitations exist in design. It will also tackle why there hasn't been a more widespread adoption of CGM systems considering the technology has been on the market for a decade now. It will dive into a variety of potential market drivers, such as, first mover's advantage, pricing, product attributes and reimbursement coverage. It will emphasize the two US leaders, Medtronic and Dexcom and analyze the companies by comparing their revenue and underlying strategies. Finally the thesis will cover emerging technologies that could pose a market threat to incumbents.
by Shweta Humad Sharma.
M.B.A.
24 pages
eng
Massachusetts Institute of Technology
M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.
http://dspace.mit.edu/handle/1721.1/7582
Sloan School of Management.
Continuous glucose monitoring and U.S. market strategy
CGM and U.S. market strategy
Thesis
application/pdf
false
Publication
unknown
unknown
<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="fb76a846-7a19-4200-b81d-52e6a1ae6952">
<Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type>
<Language>eng</Language>
<Title>Continuous glucose monitoring and U.S. market strategy</Title>
<Subtitle>CGM and U.S. market strategy</Subtitle>
<PublishedIn>
<Publication>
</Publication>
</PublishedIn>
<PublicationDate>2014</PublicationDate>
<Authors>
<Author>
<DisplayName>Sharma, Shweta Humad</DisplayName>
<Affiliation>
<OrgUnit>
</OrgUnit>
</Affiliation>
</Author>
</Authors>
<Editors>
</Editors>
<Publishers>
<Publisher>
<DisplayName>Massachusetts Institute of Technology</DisplayName>
<OrgUnit />
</Publisher>
</Publishers>
<License>http://dspace.mit.edu/handle/1721.1/7582</License>
<Keyword>Sloan School of Management.</Keyword>
<Abstract>There are about 25M (million) diabetics in the US alone, of which only 5-10% of the type 1 diabetics (1M) market has been penetrated with continuous glucose monitoring (CGM) devices. This thesis will provide an overview of the glucose monitoring, then focus on who the key market players for CGM are. Ensuing sections will explore product offerings, understanding what features patients care for and what critical limitations exist in design. It will also tackle why there hasn't been a more widespread adoption of CGM systems considering the technology has been on the market for a decade now. It will dive into a variety of potential market drivers, such as, first mover's advantage, pricing, product attributes and reimbursement coverage. It will emphasize the two US leaders, Medtronic and Dexcom and analyze the companies by comparing their revenue and underlying strategies. Finally the thesis will cover emerging technologies that could pose a market threat to incumbents.</Abstract>
<Access xmlns="http://purl.org/coar/access_right"
>
</Access>
</Publication>